Healthcare Utilization in People with Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy

Authors

  • Robert H. Dworkin PhD,

    1. From the Departments of *Anesthesiology and Neurology and Center for Human Experimental Therapeutics, School of Medicine and Dentistry, University of Rochester, Rochester, New York; §NeurogesX, Inc., San Mateo, California; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; #Strategic Therapeutics, LLC, Tucson, Arizona; and **Sissi Pham Consulting, Inc., Chapel Hill, North Carolina.
    Search for more papers by this author
  • Christopher J. Panarites PhD,

    1. From the Departments of *Anesthesiology and Neurology and Center for Human Experimental Therapeutics, School of Medicine and Dentistry, University of Rochester, Rochester, New York; §NeurogesX, Inc., San Mateo, California; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; #Strategic Therapeutics, LLC, Tucson, Arizona; and **Sissi Pham Consulting, Inc., Chapel Hill, North Carolina.
    Search for more papers by this author
  • Edward P. Armstrong PharmD,

    1. From the Departments of *Anesthesiology and Neurology and Center for Human Experimental Therapeutics, School of Medicine and Dentistry, University of Rochester, Rochester, New York; §NeurogesX, Inc., San Mateo, California; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; #Strategic Therapeutics, LLC, Tucson, Arizona; and **Sissi Pham Consulting, Inc., Chapel Hill, North Carolina.
    Search for more papers by this author
  • Daniel C. Malone PhD,

    1. From the Departments of *Anesthesiology and Neurology and Center for Human Experimental Therapeutics, School of Medicine and Dentistry, University of Rochester, Rochester, New York; §NeurogesX, Inc., San Mateo, California; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; #Strategic Therapeutics, LLC, Tucson, Arizona; and **Sissi Pham Consulting, Inc., Chapel Hill, North Carolina.
    Search for more papers by this author
  • Sissi V. Pham PharmD

    1. From the Departments of *Anesthesiology and Neurology and Center for Human Experimental Therapeutics, School of Medicine and Dentistry, University of Rochester, Rochester, New York; §NeurogesX, Inc., San Mateo, California; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, Arizona; #Strategic Therapeutics, LLC, Tucson, Arizona; and **Sissi Pham Consulting, Inc., Chapel Hill, North Carolina.
    Search for more papers by this author

Address correspondence to Robert H. Dworkin, Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642. E-mail: robert_dworkin@urmc.rochester.edu

Abstract

OBJECTIVES: To determine and compare healthcare utilization and costs for younger and older adults with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN).

DESIGN: Retrospective cohort analysis.

SETTING: Inpatient and outpatient care.

PARTICIPANTS: Patients with PHN or painful DPN were selected from administrative databases of healthcare claims and matched to controls who had a diagnosis of herpes zoster without persistent pain or a diagnosis of diabetes mellitus without neurological complications using propensity scores for demographic and clinical factors.

MEASUREMENTS: Excess per-person utilization and costs attributable to PHN and painful DPN were calculated for diagnostic procedures, medications, and interventional treatments related to neuropathic pain.

RESULTS: In both groups, the patterns of significant excess per-patient utilization and excess per-patient costs were similar for diagnostic procedures, medications, and interventional treatments, but patterns of utilization and costs of these procedures and treatments differed depending on age and the specific condition examined.

CONCLUSION: The results contribute to and expand current knowledge of the excess healthcare usage and costs of two prevalent peripheral neuropathic pain conditions and can be used in future studies of the cost-effectiveness of treatment and preventive interventions.

Ancillary